Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia.
Le Q, Tang T, Leonti A, Castro S, McKay CN, Perkins L, Pardo L, Kirkey D, Hylkema T, Call L, Manselle M, Abrahams C, Bedard K, Molina A, Brodersen LE, Loken MR, Tarlock K, Meshinchi S, Loeb KR. Le Q, et al. Among authors: molina a. Blood Adv. 2023 May 9;7(9):1666-1670. doi: 10.1182/bloodadvances.2022008303. Blood Adv. 2023. PMID: 36595452 Free PMC article. No abstract available.
Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001.
Abrahams CL, Li X, Embry M, Yu A, Krimm S, Krueger S, Greenland NY, Wen KW, Jones C, DeAlmeida V, Solis WA, Matheny S, Kline T, Yam AY, Stafford R, Wiita AP, Hallam T, Lupher M, Molina A. Abrahams CL, et al. Among authors: molina a. Oncotarget. 2018 Dec 28;9(102):37700-37714. doi: 10.18632/oncotarget.26491. eCollection 2018 Dec 28. Oncotarget. 2018. PMID: 30701025 Free PMC article.
Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL).
Wurster KD, Costanza M, Kreher S, Glaser S, Lamprecht B, Schleussner N, Anagnostopoulos I, Hummel M, Jöhrens K, Stein H, Molina A, Diepstra A, Gillissen B, Köchert K, Siebert R, Merkel O, Kenner L, Janz M, Mathas S. Wurster KD, et al. Among authors: molina a. Cancers (Basel). 2021 Oct 7;13(19):5012. doi: 10.3390/cancers13195012. Cancers (Basel). 2021. PMID: 34638496 Free PMC article.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Lancet. 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551-0. Online ahead of print. Lancet. 2025. PMID: 39798579
1,507 results